Literature DB >> 21876118

General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.

Claudia Fazi1, Lydia Scarfò, Lorenza Pecciarini, Francesca Cottini, Antonis Dagklis, Agnieszka Janus, Anna Talarico, Cristina Scielzo, Cinzia Sala, Daniela Toniolo, Federico Caligaris-Cappio, Paolo Ghia.   

Abstract

Monoclonal B-cell lymphocytosis (MBL) is classified as chronic lymphocytic leukemia (CLL)-like, atypical CLL, and CD5(-) MBL. The number of B cells per microliter divides CLL-like MBL into MBL associated with lymphocytosis (usually detected in a clinical setting) and low-count MBL detected in the general population (usually identified during population screening). After a median follow-up of 34 months we reevaluated 76 low-count MBLs with 5-color flow cytometry: 90% of CLL-like MBL but only 44.4% atypical CLL and 66.7% CD5(-) MBL persisted over time. Population-screening CLL-like MBL had no relevant cell count change, and none developed an overt leukemia. In 50% of the cases FISH showed CLL-related chromosomal abnormalities, including monoallelic or biallelic 13q deletions (43.8%), trisomy 12 (1 case), and 17p deletions (2 cases). The analysis of the T-cell receptor β (TRBV) chains repertoire showed the presence of monoclonal T-cell clones, especially among CD4(high)CD8(low), CD8(high)CD4(low) T cells. TRBV2 and TRBV8 were the most frequently expressed genes. This study indicates that (1) the risk of progression into CLL for low-count population-screening CLL-like MBL is exceedingly rare and definitely lower than that of clinical MBL and (2) chromosomal abnormalities occur early in the natural history and are possibly associated with the appearance of the typical phenotype.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21876118     DOI: 10.1182/blood-2011-05-357251

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding.

Authors:  Youn K Shim; Jane M Rachel; Paolo Ghia; Jeff Boren; Fatima Abbasi; Antonis Dagklis; Geri Venable; Jiyeon Kang; Heba Degheidy; Fred V Plapp; Robert F Vogt; Jay E Menitove; Gerald E Marti
Journal:  Blood       Date:  2013-12-17       Impact factor: 22.113

2.  Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin
Journal:  Blood       Date:  2013-07-02       Impact factor: 22.113

3.  Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones.

Authors:  Karla Plevova; Hana Skuhrova Francova; Katerina Burckova; Yvona Brychtova; Michael Doubek; Sarka Pavlova; Jitka Malcikova; Jiri Mayer; Boris Tichy; Sarka Pospisilova
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

Review 4.  Diagnosis and classification of lymphoma: Impact of technical advances.

Authors:  Elaine S Jaffe
Journal:  Semin Hematol       Date:  2018-05-29       Impact factor: 3.851

Review 5.  Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Authors:  Paolo Strati; Tait D Shanafelt
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 6.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution.

Authors:  Lesley-Ann Sutton; Richard Rosenquist
Journal:  Haematologica       Date:  2015-01       Impact factor: 9.941

7.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Valeria Spina; Alessio Bruscaggin; Sara Monti; Carmela Ciardullo; Clara Deambrogi; Hossein Khiabanian; Roberto Serra; Francesco Bertoni; Francesco Forconi; Luca Laurenti; Roberto Marasca; Michele Dal-Bo; Francesca Maria Rossi; Pietro Bulian; Josep Nomdedeu; Giovanni Del Poeta; Valter Gattei; Laura Pasqualucci; Raul Rabadan; Robin Foà; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

Review 8.  Monoclonal B cell lymphocytosis--what does it really mean?

Authors:  Andy C Rawstron
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 9.  Precursors to lymphoproliferative malignancies.

Authors:  Lynn R Goldin; Mary L McMaster; Neil E Caporaso
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

10.  [Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].

Authors:  K Hübel; M Hallek
Journal:  Internist (Berl)       Date:  2013-06       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.